Login to Your Account

Erytech's Graspa hits noninferiority, safety endpoints in phase III

By Nuala Moran
Staff Writer

Wednesday, October 1, 2014
LONDON – Erytech Pharma SA has provided definitive phase III evidence that its technique for encapsulating L-asparaginase in red blood cells prevents allergic reactions and the generation of neutralizing antibodies, while keeping the enzyme in circulation and active for longer, in the treatment of ALL.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription